Staff20192020202120222023
Personnel at the end of the year1,8371,9281,9672,2282,426
Staff turnover in EUR228,144251,141262,125231,643282,193
Turnover LabelEUREUREUREUREUR
The share: stated in EUR20192020202120222023
Shares outstanding (in mn.)39.6039.6039.6039.5739.60
Dividend per share0.040.040.040.04-
Basic earnings per share-0.13-0.80-1.61-0.813.20
P/L in EUR million under IAS/IFRS20192020202120222023
Turnover419.1484.2515.6516.1684.6
Operating income (EBIT)6.5-14.8-49.0-8.2141.1
Earnings before taxes-1.4-29.5-63.9-29.8106.3
Annual net profit/ loss-4.7-31.4-63.4-31.7127.0
Balance sheet in EUR million under IAS/IFRS20192020202120222023
Assets
Total current assets522.8556.3522.2619.4756.5
Total fixed assets611.5604.3608.8612.3687.8
Total assets1,134.31,160.61,131.01,231.71,444.3
Liabilities
Total short-term liabilities115.0105.6106.4130.2385.3
Total long-term liabilities542.4613.4644.2730.4560.1
Total provisions112.2120.3118.887.795.9
Equity capital476.9441.6380.4371.1498.9
Total liabilities1,134.31,160.61,131.01,231.71,444.3
Management:
Peter Janssen
Jörg Schüttrumpf
Ainhoa Mendizabal
Board:
Bernhard R. M. Ehmer
David Bell
Dirk Schuck
Jürgen Heilmann
Raimon Grifols Roura
Tomás Dagá Gelabert
Uta Kemmerich-Keil
Shareholding in %:
Arvernus Capital AG 0.05
BANTLEON Invest GmbH 0.01
Grifols SA 97.14
Freefloat 2.80
Address: Landsteinerstrasse 5, 63303 Dreieich
T: +49-6103-801-0
F: +49-6103-801-150
I: http://www.biotest.de
E: mail@biotest.com